Kenneth Shain, MD, PhD

home / authors / kenneth-shain-md-phd

Kenneth Shain, MD, PhD, is an associate member in the malignant hematology program and director of the Myeloma Research Center at Moffitt Cancer Center. He is also an assistant professor at the University of South Florida Morsani College of Medicine.

Articles

Referral for CAR T Should Always Be Considered in R/R Multiple Myeloma

Referral for CAR T Should Always Be Considered in R/R Multiple Myeloma

Kenneth Shain, MD, PhD
September 12th 2024

Kenneth Shain, MD, PhD, discusses why he recommends most patients with relapsed/refractory multiple myeloma be referred for evaluation to receive chimeric antigen receptor T-cell therapy.

Efficacy and Treatment-Free Interval Support Earlier Use of CAR T in R/R Myeloma

Efficacy and Treatment-Free Interval Support Earlier Use of CAR T in R/R Myeloma

Kenneth Shain, MD, PhD
August 27th 2024

Kenneth Shain, MD, PhD, discusses the rationale for giving chimeric antigen receptor (CAR) T-cell therapy in earlier lines of therapy for relapsed/refractory (R/R) multiple myeloma.

Latest Updated Articles

FDA Accepts BLA for Subcutaneous Nivolumab Across Various Solid Tumors
Published: May 6th 2024 | Updated: May 21st 2024
FDA Accepts BLA for Subcutaneous Nivolumab Across Various Solid Tumors
Immunotherapy Options for an Older Patient With Metastatic Melanoma
Published: August 18th 2023 | Updated: November 21st 2024
Immunotherapy Options for an Older Patient With Metastatic Melanoma
HER2-Low and -Ultralow Populations Benefit from T-DXd in HR+ mBC
Published: November 13th 2024 | Updated: November 21st 2024
HER2-Low and -Ultralow Populations Benefit from T-DXd in HR+ mBC
Expert Takeaway From WCLC Congress Highlights Innovative ADC Showing Promise in SCLC
Published: October 19th 2024 | Updated: November 21st 2024
Expert Takeaway From WCLC Congress Highlights Innovative ADC Showing Promise in SCLC
Second-Line Targeted Options Considered in ESR1-Mutated Breast Cancer
Published: June 6th 2024 | Updated: November 21st 2024
Second-Line Targeted Options Considered in ESR1-Mutated Breast Cancer
The Targeted Pulse: Discover Upcoming Meetings, FDA Action, and Key Insights in SCLC and mCSPC
Published: November 17th 2024 | Updated: November 21st 2024
The Targeted Pulse: Discover Upcoming Meetings, FDA Action, and Key Insights in SCLC and mCSPC